Thursday May 25th 2017

Archive for November, 2012

The politics of CCSVI research in Canada

The politics of CCSVI research in Canada

On Thursday the Senate Social Affairs, Science and Technology Committee was scheduled to go clause-by-clause through Bill S-204, a National Strategy for Chronic Cerebral Venous Insufficiency (CCSVI), before voting on it. The bill, sponsored by Liberal Senator Jane Cordy, [Read More]

Tory senators quash MS treatment bill

Tory senators quash MS treatment bill

The Conservatives have used their Senate majority to kill legislation that would have authorized a national strategy to deal with a controversial therapy for multiple sclerosis. Liberal senators say it’s shameful that Bill S-204 was squelched in committee. “This bill is [Read More]

CCSVI: Three Years Later

CCSVI: Three Years Later

It has been three years to the day since W5 first aired “The Liberation Procedure,” a ground-breaking investigation into a new condition called CCSVI. Italian vascular surgeon Dr. Paulo Zamboni proposed a novel theory that MS could be caused by blocked veins in the head [Read More]

 Page 1 of 2  1  2 »

Latest Topics

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Hospitals vary widely in how often they transition people with strokes from active treatment to comfort or hospice care [Read More]

Roche investigating case of patient illness after taking MS drug

Roche investigating case of patient illness after taking MS drug

ZURICH (Reuters) - A person in Germany treated with Roche ’s new multiple sclerosis drug Ocrevus has been diagnosed [Read More]

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]